Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 15, 2020
Reporting Period: Event date October 15, 2020; Closing expected on or about October 20, 2020.
Context: The Company entered into a securities purchase agreement for a registered direct offering of common stock.
Key Financial Metrics
Offering Details:
- Shares Issued: 833,333 shares of common stock ($0.001 par value).
- Price Per Share: $6.00.
- Expected Net Proceeds: Approximately $5.0 million (before payment of offering expenses).
- Use of Proceeds: Working capital and general corporate purposes.
Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity ratios. This report focuses solely on the capital raise transaction.
Material Changes
This filing reports a material definitive agreement (Item 1.01) and other events (Item 8.01) regarding the pricing of the offering. There is no comparative financial data provided in this document to assess changes versus prior periods.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize the net proceeds for working capital and general corporate purposes.
Outlook: The offering is scheduled to close on or about October 20, 2020, subject to customary closing conditions.
Risks and Contingencies: The transaction is subject to customary conditions to closing. The filing references a registration statement on Form S-3 (No. 333-234528) declared effective December 6, 2019.
Investor Verification Checklist
- Verify the final closing date of the offering (expected October 20, 2020).
- Confirm the actual net proceeds after deducting offering expenses.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants and obligations.
- Check the press release (Exhibit 99.1) for additional details on the purchasers.
- Monitor subsequent filings for the impact of the new shares on outstanding share count and dilution.